Elanco Animal Health Incorporated ELAN R3KPHARMA
Company Overview
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $4.71B (+6.2% YoY); net profit $-232.00M.
- Trailing 12 Months Year-on-year growth — revenue +10.2%, earnings +440.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 5.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 5.49% |
| 1 Year: | 10.20% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 440.50% |
Stock Price Performance
| 1 Year: | +34.59% |
| 6 Months: | +0.13% |
| 3 Months: | +1.22% |
| 1 Month: | +8.36% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)47.31 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ELAN Elanco Animal Health Incorporated R3KPHARMA | 23.97 | -58.46 | $11.98B | 0.00% | - | -2.98% | 5.49% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 697.10M | - | 736.20M | 770.20M | 761.10M | - | 731.10M | 781.60M | 771.30M | - | 658.00M | 586.00M | 890.00M | - | 1.24B | 1.28B | 1.13B | - | 1.23B | 1.18B | 1.03B | 1.26B | 1.06B | 1.07B | 1.21B | 1.18B | 1.03B | 1.19B | 1.24B | 1.14B | 1.37B | 1.37B |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 690.00M | 689.00M | 538.00M | 684.00M | 713.00M | 607.00M | 785.00M | 798.00M |
| Net Income | -98.30M | -30.20M | -20.70M | -161.50M | 72.70M | -62.80M | 60.20M | 16.40M | 31.50M | 35.90M | 10.00M | -9.50M | -49.00M | -53.00M | -135.00M | -322.80M | -64.00M | -206.00M | -108.00M | -105.00M | 51.00M | -10.00M | -65.00M | 103.00M | -97.00M | -1.10B | 32.00M | -50.00M | 364.00M | 67.00M | 11.00M | -34.00M | 57.00M | 54.00M |
| Diluted EPS | - | - | - | - | 0.25 | -0.21 | 0.20 | - | 0.09 | 0.10 | 0.03 | - | -0.12 | -0.13 | -0.29 | - | -0.13 | -0.42 | -0.22 | -0.22 | 0.10 | -0.02 | -0.13 | 0.21 | -0.20 | -2.22 | 0.06 | -0.10 | 0.73 | 0.13 | 0.02 | -0.07 | 0.11 | 0.11 |
| R&D Expense | - | - | 61.90M | - | 65.20M | 61.40M | 58.90M | - | 64.10M | 68.80M | 69.90M | - | 67.00M | 59.00M | 88.00M | - | 89.00M | 94.00M | 94.00M | - | 81.00M | 82.00M | 78.00M | 81.00M | 81.00M | 86.00M | 87.00M | 89.00M | 87.00M | 94.00M | 92.00M | 89.00M | 97.00M | 92.00M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.91B | 2.89B | 3.07B | 3.07B | 3.27B | 4.76B | 4.41B | 4.42B | 4.44B | 4.71B |
| Gross Profit | - | - | - | - | - | - | - | 2.49B | 2.44B | 2.59B |
| Net Income | -47.90M | -310.70M | 86.50M | 68.00M | -574.00M | -483.00M | -78.00M | -1.23B | 338.00M | -232.00M |
| Diluted EPS | - | -1.06 | 0.28 | 0.18 | -1.30 | -0.99 | -0.16 | -2.50 | 0.68 | -0.47 |
| R&D Expense | 265.80M | 251.70M | 246.60M | 270.00M | 329.00M | 369.00M | 321.00M | 327.00M | 344.00M | 368.00M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 8.94B | 8.96B | 8.99B | 17.69B | 16.48B | 15.49B | 14.36B | 12.61B | 13.36B |
| Total Equity | 7.43B | 7.02B | 7.78B | 5.20B | 5.54B | 8.46B | 7.51B | 7.29B | 6.22B | 6.10B | 6.55B |
| Cash & Equivalents | - | - | 323.40M | 474.80M | 334.00M | 495.00M | 638.00M | 345.00M | 352.00M | 468.00M | 545.00M |
| Long Term Debt | - | - | 0 | 2.44B | 2.33B | 5.57B | 6.03B | 5.45B | 5.74B | 4.28B | 3.76B |
| Total Liabilities | - | - | 1.16B | 3.76B | 3.44B | 9.22B | 8.97B | 8.20B | 8.14B | 6.52B | 6.81B |
| Current Liabilities | - | - | 643.10M | 970.70M | 818.50M | 2.08B | 1.65B | 1.70B | 1.24B | 1.31B | 1.60B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 155.90M | 173.80M | 487.30M | 224.00M | -41.00M | - | 452.00M | 271.00M | 541.00M | 560.00M |
| Investing Cash Flow | -182.10M | -964.60M | -127.00M | -235.00M | -4.78B | - | -179.00M | -169.00M | 1.16B | -279.00M |
| Financing Cash Flow | -149.60M | 847.50M | -35.20M | -305.00M | 4.95B | - | -549.00M | -83.00M | -1.49B | -275.00M |
| Capital Expenditure | -110.30M | -98.60M | -134.50M | -140.00M | -135.00M | - | -184.00M | -140.00M | -147.00M | -276.00M |
| Free Cash Flow | 45.60M | 75.20M | 352.80M | 84.00M | -176.00M | - | 268.00M | 131.00M | 394.00M | 284.00M |
| Net Change in Cash | - | - | - | - | - | - | -276.00M | 19.00M | 207.00M | 6.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | 56.3% | 54.9% | 55.0% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | -1.6% | -10.8% | 2.8% | 2.2% | -17.5% | -10.1% | -1.8% | -27.9% | 7.6% | -4.9% |
| ROE % | -0.7% | -4.0% | 1.7% | 1.2% | -6.8% | -6.4% | -1.1% | -19.8% | 5.5% | -3.5% |
| ROCE % | - | - | - | - | - | - | - | - | - | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Dodge & Cox Inc. | 13.49% | 67.40M | $1.51B |
| 2 | FMR, LLC | 11.40% | 56.95M | $1.28B |
| 3 | Blackrock Inc. | 9.78% | 48.85M | $1.10B |
| 4 | Primecap Management Company | 9.10% | 45.45M | $1.02B |
| 5 | T. Rowe Price Investment Management, Inc. | 5.75% | 28.75M | $644.59M |
| 6 | Dimensional Fund Advisors LP | 5.09% | 25.42M | $569.86M |
| 7 | Vanguard Portfolio Management LLC | 4.54% | 22.67M | $508.31M |
| 8 | Vanguard Capital Management LLC | 4.52% | 22.61M | $506.86M |
| 9 | State Street Corporation | 3.22% | 16.06M | $360.13M |
| 10 | Winslow Capital Management, LLC | 2.70% | 13.51M | $302.92M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ELAN
How Elanco Animal Health Incorporated (ELAN) Affects Rotational Strategy Timing - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxQbHlDMXVGUlFnS1hLN3lvM0IwZDg4bFRyYVR4djdCd3FZaFp3Uzk3MHJyZzY3SEdSZTVndXBsZWN1UFhqRXZDbThWYzhaRktlNGlFU25nN05wY2JvVG4wbDhGcjV3TmNTSUMtUXdVa2NMX2dFal9uNTNuX2pMY3phcXh4LWVjV2NsNERtQ3…
Elanco Animal Health (ELAN) Stock Analysis: Strong Buy Ratings and 27.41% Potential Upside - directorstalkinterviews.com
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxNT3RkTnFEQ21pTVNCRmdwN1NuazVqRU8wRkg3TW1HRDlCTkxrRzVDRUFwaGduVk5hOFFSaFl0SVc4MHpBeDEzclBFSEJJMUNfRUgxbUVNeWFFcE1WMmNqSk9PY3VyUDFmU1ZaV0VxcE4yZHZxZUp5a1hkSWFsWnlOY25Qb0RhZUtBaVBuSz…
Elanco Animal Health Stock Price Forecast. Should You Buy ELAN? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE9YcmpWeDRTdXpDTjNCUUhjVG8xVGdPVVhJbEFKOUNIQk1zdEJySFVuUHlUYnBBZnRPTHIxU1Z0Mkh6Uk5BbmxvbA?oc=5" target="_blank">Elanco Animal Health Stock Price Forecast. Should You Buy ELAN?</a>&n…
Elanco Animal Health (ELAN) Expands Kansas Manufacturing, Is The Stock 21% Undervalued? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxPZkt4NHg1VFhENjVwUVgxNXdfdFI0dDg3TkJ6ZDJkMEtEWG1YWUFnRS1IUGNiekNlRkF5ZUxKQlVpT3E0YV8tcm10OHZtMWtLSGN0LXc2dEtveVFoczlnTEtoaXQ0dG9RaEJxcjFvUkJMVTlPMDN1eVZtQm41amFVZXBab1dXV2JYZy1UbD…
Elanco (NYSE: ELAN) director buys 40K shares, stake now 188,647 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxPNVNNV21pWVBBRDIyRkdoQ2RCYTBVRjVYTFdBOVdMNEhqbmlSLWpVNTZ2UkI2d0YtektIX0NsQlRQUmRPYjdxdUpLMXdaUnVzRUI5RHhzZUlaMEs1clhHM2ZYbU5QWTNDM2pFWUVFVkM4Wkg3eWJmT29ZWEFjSXJjQXNSTndqSEltU0ZNVz…
Why Elanco Animal Health (ELAN) Stock Is Down Today - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxOS2VkUmtsZW5DcW1vWVY5TWhFNkMtSDNUdGlvbGw1SnJMaTZ4Z0k3OE9TdWE1RFVFNTRNMnRjakdjTzNsZHJQM3FIaC05cmR5SXJKckJ4YTRIMUQyMUNwOXV6WG1GM3F3VDlPUko0V2JfM3NwWm9PSXN4ck11ejVsaUpvRzQ1ZXJxODF3WV…
ELAN — Frequently Asked Questions
What is the current share price of Elanco Animal Health Incorporated (ELAN)?
As of 2026-09-19 21:16 PDT, Elanco Animal Health Incorporated (ELAN) trades at $23.97 on NYSE. Its 52-week range is $17.35 to $26.84.
What is the market capitalisation of ELAN?
Elanco Animal Health Incorporated (ELAN) has a market capitalisation of $11.98B on NYSE.
What is the P/E ratio of ELAN?
ELAN trades at a trailing price-to-earnings (P/E) ratio of -58.46. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.79.
What is the return on equity (ROE) of ELAN?
ELAN has a return on equity (ROE) of -2.98%.
Is ELAN a good stock to buy?
This page provides a data-driven analysis of Elanco Animal Health Incorporated (ELAN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.